Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Tonix Pharmaceuticals (NASDAQ:TNXP - Free Report) from a sell rating to a hold rating in a research report released on Thursday morning.

Separately, Noble Financial reissued an "outperform" rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th.

Tonix Pharmaceuticals Price Performance

Shares of TNXP traded up $7.53 during mid-day trading on Thursday, hitting $36.46. 2,259,281 shares of the stock were exchanged, compared to its average volume of 871,021. The company has a market cap of $267.07 million, a PE ratio of -0.01 and a beta of 1.63. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm has a 50-day moving average of $20.40 and a two-hundred day moving average of $21.55. Tonix Pharmaceuticals has a 52-week low of $6.76 and a 52-week high of $574.08.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($3.23) by $0.39. The firm had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities analysts predict that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current year.

Insider Buying and Selling at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 4,000 shares of the stock in a transaction on Thursday, May 15th. The stock was acquired at an average price of $21.55 per share, with a total value of $86,200.00. Following the completion of the acquisition, the chief executive officer now owns 4,005 shares in the company, valued at $86,307.75. The trade was a 80,000.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.03% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in TNXP. Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth about $40,000. Two Sigma Investments LP acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth about $66,000. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth about $72,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth about $162,000. Finally, IFP Advisors Inc acquired a new stake in shares of Tonix Pharmaceuticals during the first quarter worth about $179,000. Institutional investors and hedge funds own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.